Glomerular scarring: can we delay or even reverse glomerulosclerosis by RAAS inhibition?
Moeller
Marcus J
MJ
Department of Nephrology and Clinical Immunology, University Hospital of RWTH Aachen University, Aachen, Germany. mmoeller@ukaachen.de
D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D002921:Cicatrix / Q000503:physiopathology / Q000517:prevention & control; D004195:Disease Models, Animal; D005923:Glomerulosclerosis, Focal Segmental / Q000503:physiopathology* / Q000517:prevention & control*; D006801:Humans; D007678:Kidney Glomerulus / Q000187:drug effects / Q000473:pathology*; D050199:Podocytes / Q000187:drug effects / Q000473:pathology; D051381:Rats; D012084:Renin-Angiotensin System / Q000187:drug effects / Q000502:physiology*
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors